Abstract: Provided herein are chimeric polypeptides that may be used, e.g., for the diagnosis of or vaccination against Ehrlichia chaffeensis and/or Ehrlichia canis.
Abstract: Methods and devices of determining one or more of a male's likely fertility and health using an indicator are described herein. The indicator can measure one or more or the sperm quantity, sperm quality, and sperm motility. The methods can be regularly repeated to track one or more of likely fertility and health.
Abstract: A stimuli-responsive surface (3) comprising a substrate (20) on which is located a switchable molecule (2) which has a functional moiety (22) associated therewith, wherein the switchable molecule (2) has a first equilibrium state (2A) in which access to the functional moiety (22) is inhibited and a second stimulated state (2B), in which access to the functional moiety (22) is permitted.
Abstract: The invention provides a method of increasing an amount of oral immunoglobulin A (IgA) and/or inhibiting oral pathogens in a subject in need thereof, which utilizes a composition including a therapeutically effective amount of probiotics as an effective ingredient. The probiotics include Lactobacillus plantarum LPL28, which can efficiently increase the amount of oral IgA and/or inhibit the oral pathogens, and thus have a potential to prevent teeth cavities and/or periodontal diseases.
Abstract: The present invention relates to a composition comprising Lactobacillus rhamnosus GG (LGG) (ATCC 53103) and/or a bioactive extract of LGG to increase the expression of filaggrin or profilaggrin, for use in treating skin or mucosa barrier dysfunctions or defects. The present invention also comprises the use of a composition comprising Lactobacillus rhamnosus GG (LGG) (ATCC 53103) and/or a bioactive extract of LGG to increase the expression of filaggrin or profilaggrin, for use in the manufacture of a medicament for use in treating skin barrier dysfunctions. Also disclosed is a use of a composition comprising Lactobacillus rhamnosus GG (LGG) (ATCC 53103) and/or a bioactive extract of LGG to increase the expression of filaggrin or profilaggrin, for use in the manufacture of a cosmetic composition for use in improving the appearance and/or texture of the skin.
Abstract: The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.
Abstract: An immunogenic composition is provided herein. The immunogenic compositions are used to identify and select immunogenic antigens that elicit immune responses in a subject and may be subsequently used in multi-antigen vaccine compositions against one or more diseases or conditions. According to some embodiments, the immunogenic composition may include a plurality of nucleic acid fragments or minigenes derived from a nucleic acid library, wherein each nucleic acid fragment encodes a different antigen or functional portion thereof, and wherein the different antigens or functional portions thereof are associated with one or more disease or condition. The immunogenic composition may also include a delivery medium loaded with the plurality of nucleic acid fragments and in some embodiments, the delivery medium is loaded with nucleic acid fragments in such a way that individual antigen presenting cells receive only a subset of the nucleic acids within a vaccine in order to minimize antigenic competition.
Abstract: A recombinant coronavirus vaccine is provided. Methods of making and delivering the coronavirus vaccine also are provided. A microneedle array is provided, along with methods of making and using the microneedle array.
Type:
Grant
Filed:
November 30, 2021
Date of Patent:
August 29, 2023
Assignee:
UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
Andrea Gambotto, Louis Falo, Jr., Eun Kim
Abstract: The present invention provides a combination containing (1) a composition containing a live bacterium of Bacteroides vulgatus isolated from nature, and (2) a composition containing a live bacterium of Bacteroides dorei isolated from nature.
Type:
Grant
Filed:
February 8, 2019
Date of Patent:
August 22, 2023
Assignee:
NOSTER INC.
Inventors:
Tomoya Yamashita, Takuo Emoto, Naofumi Yoshida
Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
Type:
Grant
Filed:
April 5, 2021
Date of Patent:
August 22, 2023
Assignee:
Seres Therapeutics, Inc.
Inventors:
Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey Von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
Abstract: An immunogenic composition, a periodontal vaccine formulation containing the immunogenic composition, and methods for treating or preventing periodontal disease are provided, where the methods involves administering an immunologically effective amount of the composition or vaccine formulation to a subject.
Abstract: An oral pharmabiotic system is disclosed for improving oral, dental, and systemic health by repopulating and reshaping the flora within a patient's oral environment in a manner that overcomes the deficiencies of prior oral probiotic products. By formulating the pharmabiotic system as a strip for adhesive placement within a patients' oral cavity, preferably against the buccal mucosa, alveolar mucosa, oral labial mucosa, or a dental appliance, and configuring the parameters of the strip such that neither disadhesion nor complete dissolution occurs for at least a period of at least three hours during daytime use and at least six hours during nighttime use, the probiotic payload contained within may remain in the oral cavity for a sufficient length of time required for the probiotics to activate, replicate, and displace existing harmful oral pathobiotics.
Abstract: Provided herein are methods, compositions and kits for preventing and treating malaria. Also included herein are kits for preventing and treating malaria.
Type:
Grant
Filed:
January 11, 2021
Date of Patent:
July 4, 2023
Assignee:
RHODE ISLAND HOSPITAL
Inventors:
Jonathan Kurtis, Dipak K. Raj, Alok Das Mohapatra, Jenna Zuromski
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50, v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
Type:
Grant
Filed:
April 2, 2021
Date of Patent:
June 27, 2023
Assignee:
CYTIVA BIOPROCESS R&D AB
Inventors:
Gustav José Rodrigo, Tomas Bjorkman, Mats Ander, Jesper Ulf Hansson
Abstract: A method of testing an antibiotic susceptibility includes dispensing and cultivating sample solution into culture wells including one or more comparative wells and a plurality of antibiotic wells receiving two or more kinds of antibiotics, respectively, receiving the sample solution into a plurality of preprocessing wells each including magnetic particles and fluorescent particles that bond to one or more kinds of bacteria such that the bacteria and the magnetic particles and fluorescent particles bond to each other, receiving the sample solution into a plurality of image wells having magnetic members thereunder such that the magnetic particles bonding to the bacteria are arranged on the bottoms of the image wells, removing the sample solution from the image wells that have undergone the planarizing step, taking fluorescent images of the image wells washed in the washing step, and determining an antibiotic tolerance/susceptibility of the sample solution by analyzing the fluorescent images.
Abstract: The present invention relates to modified Mannheimia haemolytica (M. haemolytica) lktCA gene cluster cassettes, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions. Also described herein are Mycoplasma bovis (M. bovis) protective antigens, compositions comprising such antigens, methods of using such antigens and compositions, and kits comprising such antigens and compositions. Also described herein are modified M. haemolytica lktCA gene cluster cassettes engineered to express M. bovis protective antigens, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions.
Type:
Grant
Filed:
March 2, 2021
Date of Patent:
June 20, 2023
Assignee:
The United States of America, as represented by The Secretary of Agriculture
Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
Abstract: Viral vectors are provided for use as genetic immunotherapeutic agents, including preventive and therapeutic vaccines as well as compositions to enhance cellular immune responses and innate immune responses. The vectors are particularly useful for treating or preventing cancer and infectious diseases. The vectors include lentiviral vectors that encode one or more antigens, a combination of adjuvants, and optionally may encode one or more soluble and secreted checkpoint inhibitor molecules. The adjuvants include latent membrane protein 1 (LMP1) from Epstein Barr virus and a fusion protein including LMP1 with in which the intracytoplasmic domain has been replaced by human IPS1 or a variant thereof capable of activating the STING pathway. The vector-encoded sequences are codon optimized for human expression.
Abstract: A method for preparing a shelf stable spore-containing probiotic alimentary additive is disclosed, the method including providing a liquid slurry including spores from at least one spore-forming probiotic bacterial strain, a saccharide, and a humectant; and pasteurizing the liquid slurry to yield the alimentary additive. The alimentary additive may have a water activity (Aw) of less than about 0.7. The alimentary additive may have a pH from about 2.0 to 9.5. A plurality of the spores may remain in an un-germinated state and uniformly suspended for at least two months after the pasteurizing to yield a shelf stable spore-containing probiotic alimentary additive.
Type:
Grant
Filed:
April 23, 2020
Date of Patent:
June 13, 2023
Assignee:
Kerry Group Services International Limited
Inventors:
Benjamin George, Howard Cash, Joseph M. Bradley, Nusair Imam, Stephen G. Cobbe, Eileen O'Shea
Abstract: The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and/or for use in a prophylactic and/or therapeutic treatment of a disease.